Long-term outcomes of kids with childhood-onset systemic lupus erythematosus (cSLE) are uncommon, but this cSLE cohort analysis suggests that SLE significantly impacts their future education, vocation, and employment as they reach adulthood.
All News
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Dr. Jack Cush reviews and discusses more than a dozen news and journal articles from the past week on RheumNow.com.
A full year from the onset of the SARS-COV-2 pandemic, rheumatologists are still seeing the consequences of COVID, with many patients avoiding usual care, follow-up visits, routine lab testing and with many self-stopping their antirheumatic meds, because it seemed like the right thing to do.
Dr Jack Cush gives his spin on this week's RheumNews and Rheum Research from RheumNow.com.
Medscape offers up an informative overview of the newly described syndrome called VEXAS discovered by researchers at the National Institutes of Health.
Does uric acid contribute to the risk of hypertension (HTN)? A recent cohort trial shows that allopurinol in young adults does not sufficiently lower blood pressure (BP).
Serious Infections Still Common in Vasculitis
Serious infections occurred more frequently among patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis who were given induction therapy with cyclophosphamide compared with rituximab (Rituxan), Greek researchers found.
Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow.com.
Pegloticase is indicated in the treatment of severe gout patients but prolonged use may be limited by immunogenicity to the PEG moiety. A randomized, controlled trial has shown that concomitant mycophenolate mofetil (MMF) may prolong the efficacy of pegloticase in gout.
